Valuation
- Market cap
- 174,787,000
- Revenue TTM
- $16,960,000
- Net income TTM
- $-23,880,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -140.80%
- Debt to equity
- 0.00
Trading
- Volume
- 47,900
- Avg volume
- 86,652
- Day's range
- $13.43 – $13.78
- Shares out
- 12,852,000
- Stochastic %K
- 27%
- Beta
- 0.09
- Analysts
- Strong Sell
- Price target
- $30.67
Company profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals bu...
Show more
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 7 797 14100
- Website
- https://www.mediwound.com
- Address
- 42 Hayarkon Street, Yavne, Israel
Latest news
No headlines yet.
